CpGs that were significant in our replication analysis of DNMT3A CHIP were more likely than other CpGs to be significantly associated with a DNMT3A mutation in the AML patients (OR = 19.6, P < 2 × 10−16). The gene discussed is DNMT3A; the disease is acute myeloid leukemia.